ClinicalTrials.gg

Program

Daunorubicin

Also written as “daunorubicin + cytarabine”, “daunorubicin hydrochloride” and “CPX-351 (Cytarabine:Daunorubicin) Liposome Injection”.

Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms, led by 7 companies.

Furthest: phase 3, since Oct 16, 20067 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals10 open or runningphase 1since Oct 16, 2006Oct 16, 2006none ahead
Kanisa Pharmaceuticals10 open or runningphase 2since Aug 9, 2005Aug 9, 2005none ahead
Kura Oncology11 open or runningphase 3since May 16, 2025May 16, 2025Nov 2031phase 3 · NCT07007312
Novartis10 open or runningphase 1since Oct 6, 2004Oct 6, 2004none ahead
Pfizer10 open or runningphase 3since Dec 21, 2017Dec 21, 2017none ahead
Sichuan Biokin Pharmaceutical11 open or runningphase 3since Nov 20, 2025Nov 20, 2025Dec 2027phase 3 · NCT07255872
Sumitomo Pharma10 open or runningphase 1since Sep 27, 2017Sep 27, 2017none ahead

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2004First study: phase 1 study in Leukemia, Myeloid, AcuteNew to NovartisNovartis · NCT00093600 · 69 enrolled · United States, Germany
  2. Aug 9, 2005Kanisa Pharmaceuticals's first study: phase 2 study in Leukemia, MyeloidNew to Kanisa PharmaceuticalsKanisa Pharmaceuticals · NCT00129168 · 100 enrolled
  3. Oct 16, 2006Jazz Pharmaceuticals's first study: phase 1 study in Hematologic NeoplasmsNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT00389428 · 48 enrolled · United States
  4. Sep 27, 2017Sumitomo Pharma's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Sumitomo PharmaSumitomo Pharma · NCT03298984 · 32 enrolled · United States
  5. Dec 21, 2017Pfizer's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to PfizerPfizer · NCT03416179 · 730 enrolled · United States, Australia, Austria and more
  6. May 16, 2025Kura Oncology's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT07007312 · 1,300 planned · United States, Australia, Belgium and more
  7. Nov 20, 2025Sichuan Biokin Pharmaceutical's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07255872 · 216 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteSichuan Biokin Pharmaceutical · NCT07255872
  2. Nov 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteKura Oncology · NCT07007312

TargetBeta

TOP2A →read by rule
“DNA topoisomerase II alpha inhibitor; DNA topoisomerase II alpha inhibitor; DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule

Other programs on TOP2A

ProgramCompanyFurthest phaseStudies
DoxorubicinruleHoffmann-La Rochephase 461
EtoposideruleHoffmann-La Rochephase 328
amrubicinruleBristol-Myers Squibbphase 39

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07255872Leukemia, Myeloid, Acute · China3RecruitingSichuan Biokin PharmaceuticalDec 2027216
NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3RecruitingKura OncologyNov 20311,300
NCT03416179Leukemia, Myeloid, Acute · United States, Australia, Austria and more3CompletedPfizerJun 5, 2020730
NCT03298984Leukemia, Myeloid, Acute · United States1CompletedSumitomo PharmaMar 20, 202032
NCT00389428Hematologic Neoplasms · United States1CompletedJazz PharmaceuticalsDec 200848
NCT00129168Leukemia, Myeloid2CompletedKanisa PharmaceuticalsMar 2008100
NCT00093600Leukemia, Myeloid, Acute · United States, Germany1CompletedNovartisJun 201169

How it is read

Names in the registry

  • “Daunorubicin”, 4 entries
  • “daunorubicin + cytarabine”, 1 entry
  • “daunorubicin hydrochloride”, 1 entry
  • “CPX-351 (Cytarabine:Daunorubicin) Liposome Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.